Cephalon Adds Amrix To Pain Portfolio From ECR Pharmaceuticals Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to launch the drug in the fourth quarter using its pain and CNS sales forces, CEO Baldino tells “The Pink Sheet” DAILY.
You may also be interested in...
Amrix And Treanda Take-up Bodes Well For Cephalon
New drugs help firm move on from fading Actiq, beset by generic erosion.
Amrix And Treanda Take-up Bodes Well For Cephalon
New drugs help firm move on from fading Actiq, beset by generic erosion.
Cephalon Earnings Beat Consensus, But Opinion Split On Future
"Sentiment-driven" stock due for growth year, analyst tells "The Pink Sheet" DAILY